Luis Rangel, MD
Hematology & Oncology · Hialeah, FLNPI 1487645149
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,677 of the $24,447 with a category attached, or 64.1%. It is spread thinly across 60 manufacturers, the largest accounting for just 23.0%. Reporting peaked in 2024 at $11,258 and has fallen 59.6% since, to $4,550 in 2025.
Across 818 payments — averaging $29.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$6K
- Novartis$4K
- Johnson & Johnson$3K
- Pfizer$2K
- Bristol Myers Squibb$1K
- AstraZeneca$1K
- plus $9K from 54 others
Across 14 payments — averaging $14,767 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Urogen Pharma, Inc.$66K
- Beone Medicines Ltd.$56K
- Merck$47K
- Sanofi$38K
What the payments were for
- Speaking & faculty fees$5,32922%
- Food & beverage$15,67764%
- Education$9264%
- Other$2,51510%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$4,954
- TRELSTAR$500
- Monarch Platform$155
How this compares
$24,447 in reported general payments places this provider in the 75th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 77 | $1,207,846 |
| CalquenceAcalabrutinib Maleate | 77 | $1,150,253 |
| BosulifBosutinib | 53 | $824,787 |
| ImbruvicaIbrutinib | 42 | $696,851 |
| VerzenioAbemaciclib | 41 | $663,486 |
| CabometyxCabozantinib S-Malate | 13 | $596,483 |
| NubeqaDarolutamide | 43 | $584,891 |
| VenclextaVenetoclax | 41 | $570,368 |
| Abiraterone Acetate | 213 | $568,560 |
| TagrissoOsimertinib Mesylate | 32 | $548,057 |
| KisqaliRibociclib Succinate | 32 | $457,542 |
| TasignaNilotinib Hcl | 23 | $441,542 |
| LumakrasSotorasib | 12 | $260,994 |
| PomalystPomalidomide | 11 | $257,370 |
| RevlimidLenalidomide | 19 | $228,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Bosulif, Eliquis | $1,565 | $2,046,049153 claims |
| AstraZenecaCalquence, Tagrisso | $1,031 | $1,698,311109 claims |
| NovartisKisqali, Tasigna | $3,576 | $899,08455 claims |
| AbbVieVenclexta, Lupron Depot | $420 | $723,91367 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $52 | $696,85142 claims |
| Lilly USA, LLCVerzenio | $286 | $663,48641 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel, Opdivo | $5,622 | $660,33636 claims |
| Exelixis Inc.Cabometyx | $24 | $596,48313 claims |
| BayerNubeqa | $85 | $584,89143 claims |
| AmgenLumakras | $135 | $260,99412 claims |
| Bristol Myers SquibbRevlimid | $1,135 | $228,68719 claims |
| Johnson & JohnsonErleada, Procrit | $2,806 | $210,12336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Hialeah
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
- Shahram MoriOrlando$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.